Fig. 11.

Differences in mutations, biological functions, and response to medication between risk groups. (A) Frequency of mutations in DEGs within patients with high-risk scores and (B) low-risk scores. (C) The correlation between TMB scores and risk groups. (D) The GO enrichment analyses in high- and (B) low-risk samples. (F-M) Sensitivity to (F) gemcitabine, (G) methotrexate, (H) vinorelbine, (I) sunitinib, (J) camptothecin, (K) gefitinib, (L) cisplatin, and (M) doxorubicin in the different risk groups.